



New Zealand standardised oral formulation batch sheet

Gabapentin suspension 100 mg/mL (60mL)

| | | | | |
|-----------------|--|---------------------|--|-------------------------------------|
| Patient's name | | Storage condition | In a refrigerator | At room temperature |
| NHI | | Temperature | 2-8°C | ≤ 25°C |
| Date compounded | | Shelf life | Precipitates | 30 days |
| Batch number | | Recommended storage | There is a risk of precipitation if the solution is stored in a refrigerator | <input checked="" type="checkbox"/> |

Ingredients required and formula:

| Ingredient | Supplier | Batch number | Expiry date | Standard formula | Quantity dispensed | Dispensed by | Checked by |
|----------------------------|----------|--------------|-------------|------------------|--------------------|--------------|------------|
| Gabapentin 300 mg capsules | | | | 20 capsules | | | |
| Ora-Blend® | Perrigo | | | to 60 mL | | | |
| OR | | | | | | | |
| Ora-Plus® | Perrigo | | | 30 mL | | | |
| Ora-Sweet® | Perrigo | | | 30 mL | | | |

Ora-Blend SF® or Ora-Sweet SF® (sugar free) can be substituted? Yes

Calculations performed by

Calculations checked by (pharmacist)

Area cleared for processing by

Instructions to compound suspension:

- If Ora-Blend® unavailable:** Pre-mix the Ora-Plus® and Ora-Sweet® to form the diluent.
- Empty the contents of the capsules into the mortar.
- Grind the powder very, very well with the pestle.
- Add diluent (Ora-Blend® or prepared diluent) to form a smooth paste.
- Gradually add the diluent and transfer to the final measuring flask, rinsing the mortar well. Mix well.
- Make up to the final volume and mix well.
- Label and package product appropriately.

Labels

Attach product label and auxiliary labels:

Label checked by



New Zealand standardised oral formulation batch sheet

Gabapentin suspension 100 mg/mL (60mL)

| | | | |
|--|--|-----------------------|--------------|
| Final yield | _____ mL | Checked by | |
| Final appearance of product | White to pale pink suspension. | | |
| Container | Amber plastic mission bottle. | | |
| Compounded by | <i>Name:</i> | <i>Signature:</i> | <i>Date:</i> |
| Final check and product release | <i>Name:</i> | <i>Signature:</i> | <i>Date:</i> |
| Special instructions: 1. Shake well before use. 2. Storage at room temperature required as precipitation has been observed at temperatures below 8°C. ¹ | | | |
| References: 1. Friciu M, Roullin VG, Leclair G. <i>PLoS One</i> , 2017; 12 (4): e0175208. 2. Nahata MC. <i>Pediatr Neurol</i> , 1999; 20 (3): 195-197. | | | |
| Prepared by | New Zealand Compounding Working Group | | |
| Approved by | Medication Safety Expert Advisory Group of Health Quality and Safety Commission NZ | | |
| Hosted by | Pharmaceutical Society of New Zealand Standard Formulations in the Practice Support section of the PSNZ website | | |
| Version number | 3.0 | Version approval date | 17/07/19 |
| Document review due | 01/08/21 | | |

Disclaimer: this batch sheet has been designed to provide guidance and standardised formulations for New Zealand pharmacists. Please read and familiarise yourself with the general guidance for compounding oral liquids (available on the PSNZ web site) before use. Information was considered accurate at the time of publication.